Arizona Medicaid spending on GLP-1 drugs

How much did Arizona Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $98.3 million for GLP-1 drugs paid through Arizona Medicaid in 2025, across at least 93,645 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 76 rows of 215, so these figures are floors.

Pharmacies were reimbursed at least $17.3 million for GLP-1 drugs paid through Arizona Medicaid in 2026 (quarter 1 only, as posted so far), across at least 15,751 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 18 rows of 55, so these figures are floors.

By year and ingredient

2020at least $513,844No data$17,178,439at least $1,769,658at least $6,834,664at least $131,299Suppressedat least $26,427,904
2021at least $1,256,786No data$18,958,338at least $14,441,510at least $2,687,258$175,055Suppressedat least $37,518,946
2022at least $3,452,416at least $190,913$17,558,312at least $43,065,854at least $665,993$248,033Suppressedat least $65,181,522
2023at least $5,980,924at least $1,755,942$14,388,716at least $61,651,740at least $629,739$249,820Suppressedat least $84,656,880
2024at least $7,562,288at least $3,919,152at least $6,380,908at least $71,272,642at least $763,674$183,884Suppressedat least $90,082,548
2025at least $8,876,256at least $7,030,865at least $2,090,687at least $79,913,216at least $214,672$126,925Suppressedat least $98,252,621
2026 (Q1)at least $1,490,027at least $1,526,653at least $286,682at least $13,888,803at least $49,939$19,469Suppressedat least $17,261,573

By product, 2025

Ozempicat least $7,422,990at least 6,97411 of 23
Rybelsusat least $335,857at least 3151 of 12
Wegovyat least $1,117,409at least 8651 of 21
Mounjaroat least $7,030,865at least 6,1267 of 31
ZepboundSuppressedSuppressed17 of 17
Liraglutide (generic name listing)at least $1,091,220at least 2,57412 of 33
SaxendaSuppressedSuppressed3 of 3
Victozaat least $999,467at least 1,5434 of 13
Trulicityat least $79,913,216at least 74,8559 of 41
Bydureonat least $19,412at least 251 of 2
Byettaat least $121,755at least 1486 of 8
Exenatide (generic name listing)at least $73,505at least 943 of 6
Soliqua$126,9251260 of 4
XultophySuppressedSuppressed1 of 1

By quarter, 2025

Q1 2025at least $23,210,558at least 22,47818 of 53
Q2 2025at least $24,578,165at least 23,31422 of 55
Q3 2025at least $25,860,775at least 24,48820 of 55
Q4 2025at least $24,603,122at least 23,36516 of 52

By quarter, 2026 (posted so far)

Q1 2026at least $17,261,573at least 15,75118 of 55

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.